Results 51 to 60 of about 251 (118)
PENTADECAPEPTIDE BPC 157: PANACEA OR OVERHYPED PEPTIDE?
<p>Interest in Pentadecapeptide BPC 157, an oligopeptide originally derived from human gastric juice, has grown substantially among members of the fitness community in the past few years due to its wide range of purported and previously reported effects on improving health and enhancing performance.
Joseph A. Giandonato, Victor Tringali
openaire +1 more source
BPC 157, known as the “Body Protection Compound”, is a pentadecapeptide isolated from human gastric juice that demonstrated its pleiotropic beneficial effects in various preclinical models mimicking medical conditions, such as tissue injury, inflammatory
Michalina Józwiak +3 more
doaj +1 more source
Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats [PDF]
Serotonin syndrome commonly follows irreversible monoamine oxidase (MAO)-inhibition and subsequent serotonin (5-HT) substrate (in rats with fore paw treading, hind limbs abduction, wet dog shake, hypothermia followed by hyperthermia). A stable gastric pentadecapeptide BPC 157 with very safe profile (inflammatory bowel disease clinical phase II, PL-10 ...
Boban Blagaić, Alenka +12 more
openaire +2 more sources
Spinal Instability in Rats Counteracted by Pentadecapeptide BPC 157
To induce spinal instability, we focused on bilateral facetectomy in rats and possible therapeutic benefit with the stable gastric pentadecapeptide BPC 157 given in the drinking water. Recently, using a well‐designed rat model (L2‐L3 compression), we demonstrated that the stable gastric pentadecapeptide BPC 157 improved the spinal cord injury (FASEB J ...
Dokuzovic, Stjepan +9 more
openaire +1 more source
Stable Pentadecapeptide BPC 157 and Vesicovaginal Fistulas in Rats
Aim Frequently, large vesicovaginal fistulas need operation treatment. Stable gastric pentadecapeptide BPC 157, tested in clinical trials for ulcerative colitis therapy and now multiple sclerosis (Curr Pharm Des. 2017;23(27):4012–4028; Curr Pharm Des. 2014;20(7):1126–35; Curr Pharm Des.
Rasic, Domagoj +8 more
openaire +1 more source
Pentadecapeptide BPC 157 Therapy in Rats with Cysteamine Induced‐Terminal Ileitis
Aim We introduce pentadecapeptide BPC 157 therapy in rats with cysteamine induced‐terminal ileitis, 1 h, 1 month, 2 months. We counteracted gross hyperemia, edema, erosion, bleeding, and, microscopically, significant loss of villous architecture, loss and shortening of villae and severe lymphocytic infiltrate ...
Radic, Bozo +12 more
openaire +2 more sources
The healing issue is a central, not completely understood, problem in pharmacology, approached by many concepts. One of the most well-known is Robert’s and Szabo’s concept of cytoprotection, which holds innate cell (epithelial (Robert), endothelial ...
Predrag Sikiric +15 more
doaj +1 more source
We report a simple novel rat model that combines prolonged esophagitis and parallel sphincters failure. The anti-ulcer gastric pentadecapeptide BPC 157, which was found to be stable in gastric juice, and is being evaluated in inflammatory bowel disease ...
Igor Petrovic +17 more
doaj +1 more source
Background. This rat study reveals a new point: the considerable impact of unilateral adrenalectomy, severe vascular and multiorgan failure, occlusion/occlusion-like syndrome, and the stable gastric pentadecapeptide BPC 157 therapy.
Ivan Maria Smoday +21 more
doaj +1 more source
Background/Objectives: BPC-157 (body protection compound 157) is a synthetic pentadecapeptide derived from a gastric protein fragment with reported cytoprotective and regenerative properties across multiple organ systems.
Diana-Maria Mateescu +9 more
doaj +1 more source

